A Denver federal appeals court has upheld a 2004 FDA rule declaring that dietary supplements containing ephedrine alkaloids (ephedra, or Ma huang) cannot be marketed in the United States. In a statement, FDA calls the Denver decision "consistent" with 1994 dietary supplement legislation and says the decision "supports the agency's findings" regarding the potential risks of ephedra-containing supplements. The FDA Statement is attached via the following link:

http://www.thenhf.com/FDA_on_Ruling_Upholding_Epheda_Ban.pdf